Navigation Links
Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
Date:1/31/2013

SANDY, Utah, Jan. 31, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol "RAFA" announced that it has been named one of the four national strategic Pharmaceutical Suppliers to the Russian Federation.  This important step for the company means it will receive guaranteed government contracts helping load the manufacturing facility to 100% capacity.

The Russian pharmaceutical industry supplies both the national health care system and hospital sector with 70% of medicines in physical volume. The Russian pharmaceutical market is considered to be one of the most dynamic and growing in the world. It continues to grow an average 10-12% per year since 2003 (Source: The Strategy of Development of the Pharmaceutical Industry of the Russian Federation, http://www.osec.ch/de/filefield-private/files/25703/field_blog_public_files/5244).

CEO David Anderson stated, "This is a very exciting time for the Company and we are extremely happy with the ability to be one of the four national strategic Pharmaceutical Suppliers to the Russian Federation."

As previously announced the Company will facilitate investor awareness using social media.  Follow Rafarma Pharmaceuticals on Facebook at www.facebook.com/rafarmainfo or Twitter at www.twitter.com/rafarmainfo. You can also text "RAFA" to 74499 to receive updates via text message.

Safe Harbor Statement 

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,"  "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.


'/>"/>
SOURCE Rafarma Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Issuance of $350.0 Million of 1.50% Convertible Senior Notes Due 2018
2. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
3. Ryan & Maniskas, LLP Announces Investigation of MAP Pharmaceuticals, Inc.
4. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
5. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
6. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
8. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
9. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
10. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017  International Isotopes Inc. (OTCQB: INIS) ... placement with certain investors for approximately $3.4 million of ... Series C Convertible Redeemable Preferred Stock (the "Series C ... annual rate of 6% and is convertible into common ... use the proceeds for operating capital, to pay off ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Uterine cancer Drugs Price Analysis and Strategies ... cancer market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Uterine cancer ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... ... Philpart, senior director at PolicyLink, will be the keynote speaker at its second ... and Men of Color Framework, which develops comprehensive strategies to create and expand ...
(Date:2/21/2017)... ... February 21, 2017 , ... Support of value-based care ... the secure exchange of data across industry solutions, Fogo Data Centers announces the launch ... community. A healthy community is one in which all systems work well, work ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is ... connected care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and ... providers have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets ...
(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... ... February 20, 2017 , ... Scrubbing in for his first ... Dr. Christopher Pezzi remembers the excitement of the surgeon training him. , “He was ... to do this? Don’t tell anyone, but I would do it for free,’” Dr. ...
Breaking Medicine News(10 mins):